This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.
Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

开始日期2024-12-01

申办/合作机构

University of Pennsylvania

[+1]

NCT06637189 / Not yet recruiting临床4期IIT

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients.
The aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.

开始日期2024-10-15

申办/合作机构

Theramex HQ U.K Ltd.初创企业

NCT06549855 / Not yet recruitingN/AIIT

PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer

The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.

开始日期2024-10-01

申办/合作机构

北京大学人民医院

[+7]

100 项与醋酸甲羟孕酮相关的临床结果

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的转化医学

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的专利（医药）

登录后查看更多信息

12,412

项与醋酸甲羟孕酮相关的文献（医药）

2025-01-01·Talanta

Simultaneous observation of 2H and 13C enrichment of methyl phosphonic acid via Orbitrap-IRMS with applications to nerve agent forensics

Article

作者: Fraga, Carlos G. ; Moran, James J. ; Moran, James J ; Eiler, John M ; Fraga, Carlos G ; Csernica, Timothy ; Eiler, John M.

Quantification of the stable isotopes within a compound aids forensic investigations as it provides a fingerprint which can determine that compound's source substrates, synthetic route, and possible mechanisms of degradation. Previous stable isotope studies have explored ¹³C and ²H measurements of the sarin precursors methylphosphonic dichloride (DC) and methylphosphonic difluoride (DF) as forensic signatures. However, these measurements required different sample preparations and measurement techniques. Orbitrap isotope ratio mass spectrometry (Orbitrap-IRMS) is a developing technique which can characterize multiple stable isotopes simultaneously. Here, we apply Orbitrap-IRMS to simultaneously observe the ¹³C and ²H content of methylphosphonic acid (MPA), the hydrolysis product of DC and DF, which can be used as a proxy for the isotopic content of DC and DF. Our method requires 20 min analyses and consumes ≈60 nmol of sample, with precisions of ≈0.9 ‰ (¹³C) and ≈3.6 ‰ (²H). We apply our method to both commercially acquired MPA and MPA obtained from the hydrolysis of commercially acquired DC. We validate our methods via comparison to elemental-analyzer isotope ratio mass spectrometry (EA-IRMS). The combined ¹³C and ²H measurement creates a more robust forensic tool than either isotope individually. Our results demonstrate the viability of Orbitrap-IRMS for chemical forensic measurements.

2024-12-31·Gynecological Endocrinology

Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome

Article

作者: Suh, Chang Suk ; Kim, Hoon ; Ku, Seung-Yup ; Han, Soo Jin

OBJECTIVEBoth oral contraceptive pills (OCPs) and cyclic medroxyprogesterone acetate (MPA) are widely used to control menstrual abnormalities in women with polycystic ovary syndrome (PCOS). We aimed to evaluate the chance of ovulation resumption after cessation of OCPs and MPA in women with PCOS.METHODSA retrospective study was conducted of women with PCOS who were treated with OCPs or cyclic MPA from September 2015 to March 2019. After cessation of medication, ovulation was assessed using basal body temperature and/or measurement of serum progesterone. The odds ratio for ovulation resumption was assessed with multivariable logistic regression. Additionally, doubly robust analysis was performed with inverse-probability-weighted analysis and regression adjustment based on the covariate balancing propensity score to adjust for the effect of covariates on the treatment assignment.RESULTSAmong 272 women with PCOS, 136 were prescribed OCPs and 136 were prescribed cyclic MPA. Ovulation resumed in 18.4% of women (n = 25) after cessation of MPA and in 24.3% of women (n = 33) after cessation of OCPs. The odds of ovulation resumption in MPA users were comparable with those in OCP users (adjusted odds ratio (aOR) 1.00, 95% confidence interval (CI) 0.89-1.12). After multiple imputation due to missing values, the results did not change substantially (aOR 0.99, 95% CI 0.89-1.10).CONCLUSIONSAmong women with PCOS, MPA users have a similar chance of ovulation resumption as OCP users after cessation of medication. Cyclic MPA can be a good alternative to OCPs in women for whom OCPs are contraindicated or who decline to take OCPs.

2024-12-31·Gynecological Endocrinology

Progestin-primed ovarian stimulation outcomes in in-vitro fertilization (IVF) – A systematic review of the literature

Review

作者: Di Renzo, Gian Carlo ; Lokshin, Vyacheslav Notanovich ; Kenesovna Karibayeva, Sholpan ; Feichtinger, Michael ; Margulanovna Syzdykova, Dana ; Temirkhanovna Abshekenova, Aigerim

Background: Progestin-primed ovarian stimulation (PPOS) stimulates ovaries to block the premature surge of luteinizing hormone (LH) by using micronized progesterone or a progestin during the follicular phase instead of the conventional gonadotropin-releasing hormone (GnRH) analogues or GnRH antagonists downregulating LH to obtain multi-follicle engagement. Current work aims to assess the influence of progestogen treatment on ovarian stimulation and the ability to control LH surge, its efficacy and suitability in retrieving oocytes, without affecting the embryo quality and its benefit among infertile women long-term outcomes on children compared to standard stimulation protocols. Materials and Methods: The literature review used the randomized control trials published in the Pubmed database from January 2015 to April 2021. To generate the citation list, the following keywords were used: 'progestin-primed ovarian stimulation', 'PPOS', 'micronized progesterone', 'medroxyprogesterone', and/or 'dydrogesterone'. The selected articles analyzed the cohort, intervention, and scheme of the progestin-primed ovarian stimulation protocol in controlled ovarian stimulation (COS) for in-vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI) used in Assisted Reproductive Technologies (ART). Results: Overall we concluded that PPOS for IVF/ICSI in ART results in a higher number of obtained embryos, lower incidence of OHSS, equal duration of stimulation, number of retrieved oocytes, and number of MII oocytes. It is also suggested that long-term safety in children shows no significant difference between the study and control groups. Conclusions: Despite the outcomes of progestin stimulation cycles among all cohorts, we concluded that poor ovarian responders, patients with PCOS, women of advanced age and oocyte donors benefit the most from using PPOS.

项与醋酸甲羟孕酮相关的新闻（医药）

2024-11-07

·Business Wire

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow

LONDON--( BUSINESS WIRE )--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024. Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic. Harmony P. Garges, MD, Senior Vice President and Chief Medical Officer at ViiV Healthcare, said: “ViiV Healthcare is the first company to develop and launch long-acting options and two-drug regimens, and these therapies are transforming how physicians and providers treat and prevent HIV today. We continue evaluating how diverse populations living with or impacted by HIV respond to our therapies in the real world. Data from these studies include more than 10,000 people using Vocabria + Rekambys , more than 50,000 people using Dovato and more than 1,300 people using Apretude 1 . At HIV Glasgow, ViiV Healthcare is showcasing new, compelling data from our portfolio that reinforces how our medicines impact health outcomes and contribute to ending the HIV epidemic. ” Key data to be presented at HIV Glasgow 2024 by ViiV Healthcare and its study partners will include: Analysis of cabotegravir + rilpivirine long-acting (CAB+RPV LA) in the real-world and across phase 3/3b studies : Findings from a large-scale post hoc analysis of the complete long-acting HIV treatment regimen CAB+RPV LA will be presented. The analysis, which pooled data from over 2,500 participants across four major phase 3/3b clinical trials (FLAIR, ATLAS, ATLAS-2M, and SOLAR), will compare virologic outcomes and isolated viraemic events between daily oral HIV treatment and CAB+RPV LA. 2 Furthermore, the real-world utilisation of CAB+RPV LA will be explored in an analysis of adherence and persistence in a Canadian patient support program. These analyses will add to the growing body of clinical and real-world evidence for CAB+RPV LA and offer additional insights to healthcare providers on outcomes for CAB+RPV LA in diverse populations. Data exploring the use of dolutegravir/lamivudine (DTG/3TC) in antiretroviral-naïve people living with HIV: Findings will be presented from the Fundación Huésped-sponsored DOLCE study. This is the first study to fully focus on evaluating the efficacy and safety of the 2-drug regimen DTG/3TC in people living with HIV with CD4 ≤ 200 cells/mm³. 3 Additionally, data will be shared from the phase IV D2ARLING study, which compared the efficacy and safety of DTG/3TC against a 3-drug regimen in an antiretroviral-naïve population that did not have baseline drug-resistance testing results available. 4 Many guidelines recommend baseline drug resistance testing prior to antiretroviral therapy (ART) initiation, that may not always be readily accessible, reinforcing the need and impact of these data in an antiretroviral-naïve population. Cost-effectiveness and usage patterns for long-acting HIV prevention: Findings from a cost-effectiveness study examining the economic and public-health impact of cabotegravir long-acting (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in Canada will be presented. Researchers will compare the impact of the introduction of CAB LA for PrEP against daily oral PrEP (TDF/FTC) and no PrEP usage on cost savings and quality-adjusted life years. 5 New findings from the PROTECT survey will be shared, exploring differences in interest and intention to use long-acting PrEP among men who have sex with men and heterosexual men and women in 20 European countries. 6,7 Advancing novel mechanisms of action in HIV research: New findings from the BANNER study of VH3810109 (N6LS), an investigational, broadly neutralising antibody (bNAb), will be presented. Previously presented phase IIa proof-of-concept findings from the BANNER study suggested VH109 was well-tolerated and efficacious in people living with HIV. 8 Researchers will share new findings exploring the correlation between baseline phenotypic sensitivity to N6LS and virologic response after treatment with N6LS. 9 Additional research evaluating N6LS will focus on administration and dose responsiveness, adding to the growing body of evidence supporting the bNAb as a potential new approach to treating HIV. 10 ViiV Healthcare-sponsored or supported studies to be presented at HIV Glasgow 2024: Title First Author Presentation Cabotegravir + rilpivirine long-acting Similar virologic outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virologic failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase 3/3b cabotegravir + rilpivirine long-acting studies J. Thornhill Poster Presentation Real-world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support program in Canada, preliminary results C. LaForty Poster Presentation Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long-acting (LA) CAB+RPV administration out of HIV units: the IMADART study A. Cabello Poster Presentation Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine A. Fernández Oral Presentation Use of long-acting cabotegravir and rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH-NA cohort-France M. Hessamfar Poster Presentation Results at month 7 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH) C. H. Tenorio Poster Presentation Re-suppression regimens and outcomes after virological failure in randomised controlled trials and real-world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV) A. Elias Poster Presentation Virological failure rate and emergent resistance in real-world studies evaluating long-acting cabotegravir and rilpivirine in people with baseline viral suppression M. Smuk Poster Presentation Cabotegravir long-acting for PrEP PrEP-associated stigma in Europe: findings from a real-world survey M. Schroeder Poster Presentation Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada A. Adelakun Poster Presentation Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe; the PrEPaRe study V. Cambiano Poster Presentation Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis H. Wang Oral Presentation Preparing for long-acting PrEP delivery: provider preferences for the provision of long-acting PrEP differ between MSM and heterosexual individuals in Europe H. M. L. Zimmerman Poster Presentation Intention to use long-acting PrEP among heterosexual women and men in 20 European countries – results from the PROTECT survey K. Jonas Poster Presentation Dolutegravir Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naive and pre-treated people living with HIV in Russia A. Basova Poster Presentation The analysis of metabolic parameters in people living with HIV using dolutegravir-based regimens in routine clinical practice in Russia A. Basova Poster Presentation Outcomes following prenatal exposure to DTG-containing antiretroviral therapy regimens: data from the DOLOMITE-EPPICC study R. Sconza Poster Presentation Incident hypertension with antiretroviral therapy: real-world evidence from the OPERA cohort P. Lackey Poster Presentation A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE-NEAT ID Network study J. D. Kowalska Poster Presentation Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia E. Tusch Poster Presentation Mental health in PWH: Patient-reported outcomes in the DUALIS study E. Wolf Poster Presentation Evaluating the cardiovascular risk and the achievement of target levels in low-density lipoprotein cholesterol in PLWH: Insights from the DUALIS study F. Voit Poster Presentation Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls R. Ryan Poster Presentation Efficacy and safety of dolutegravir (DTG)-based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): A single-arm clinical trial (DTG-SOT) J. Miro Poster Presentation Dolutegravir/lamivudine PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States (US) J. Slim Poster Presentation Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies D. Fox Poster Presentation An EYEWITNESS to successful diversity in antiretroviral switch studies C. V. Dam Poster Presentation CARAVEL: evaluation of real-world effectiveness and sustainability of the 2-drug regimen dolutegravir/lamivudine fixed-dose combination in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France. Two-year interim analysis results P. Philibert Poster Presentation Real world experience of DTG+3TC regimen: results from the French Dat'AIDS cohort (2015-2022) C. Allavena Poster Presentation Changes in patient-reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO-DOBLE randomized clinical trial L. Garcia-Fraile Poster Presentation Comparable efficacy and safety of dolutegravir / lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm 3 : the DOLCE study M. I. Figueroa Oral Presentation RUMBA’s week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF S. Degroote Poster Presentation Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study E. Cordova Poster Presentation Long-term efficacy and safety of Dolutegravir/Lamivudine in virologically suppressed persons with resistance to Lamivudine: Week 96 results of VOLVER clinical trial - GESIDA 11820 M. De Lagarde Poster Presentation Fostemsavir CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low-level viremia (LLV) up to Week 192 with fostemsavir (FTR)-based regimens in individuals with multidrug-resistant (MDR) HIV-1 V. Spagnuolo Encore Poster Presentation Similar efficacy, safety and CD4 T-cell increase up to Week 96 observed with fostemsavir (FTR)-based regimens in the BRIGHTE study and dolutegravir (DTG)-based regimens in the VIKING-3 study in individuals with multidrug-resistant (MDR) HIV-1 A. Castagna Encore Poster Presentation Pipeline Correlation of baseline phenotypic sensitivity with virologic response to VH3810109 (N6LS) in BANNER M. Gartland Poster Presentation VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models M. Keegan Encore Poster Presentation Additional Studies Mortality and clinical outcomes after common cancers in people A. Timiryasova Poster Presentation The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study S. Deb Poster Presentation Comparison of 4 frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study) C. Allavena Poster Presentation The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3-5 year period L. Sukumaran Poster Presentation About Dovato Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato . Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets . About Vocabria Vocabria (cabotegravir) injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class. Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for: oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection. oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection. Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant tablets should also be consulted for recommended dosing. Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets About Rekambys Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class. Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection). Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection About Apretude Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir. Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About Fundación Huésped Fundación Huésped is an Argentine organisation with a regional reach that has been working in public health since 1989, aiming to ensure the right to health and the control of diseases are guaranteed. Our comprehensive approach includes the development of research, practical solutions, and communications related to public health policies in our country and the region. Our mission is to conduct scientific research and implement preventive actions and rights-promotion initiatives to ensure access to healthcare and reduce the impact of diseases, with a focus on HIV/AIDS, viral hepatitis, vaccine-preventable diseases, and other transmissible diseases, as well as sexual and reproductive health. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com . About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024. Registered in England & Wales: GSK plc No. 3888792 ViiV Healthcare Limited No. 06876960 Registered Office: 79 New Oxford Street London WC1A 1DG ViiV Healthcare Limited GSK Medicines Research Centre Gunnels Wood Road, Stevenage United Kingdom SG1 2NY References: 1 Data on file 2 J. Thornhill, et al . Similar virologic outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virologic failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase 3/3b cabotegravir + rilpivirine long-acting studies. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 3 M. I. Figueroa, et al . Comparable efficacy and safety of dolutegravir / lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 4 E. Cordova, et al . Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 5 A. Adelakun, et al . Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 6 H. Wang, et al . Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 7 K. Jonas, et al. Intention to use long-acting PrEP among heterosexual women and men in 20 European countries – results from the PROTECT survey. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 8 P. Leone, et. al . VH3810109 (N6LS) Reduces Viremia Across a Range of Doses in ART-Naive Adults Living with HIV: Proof of Concept Achieved in the Phase IIa BANNER (207959, NCT04871113) Study. Presented at HIV Glasgow 2022, 23 – 26 October, Glasgow, Scotland. 9 M. Gartland, et al . Correlation of baseline phenotypic sensitivity with virologic response to VH3810109 (N6LS) in BANNER. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. 10 M. Keegan, et al . VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland. For media and investors only

临床2期临床结果临床3期

2024-05-23

·BioPharmaDive

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer, according to results released Thursday from two studies involving tens of thousands of women. Another hormonal regimen didnt seem to carry this same risk, researchers found.The results should help settle debate over the relative risk of cancer associated with estrogen- and progestin-based hormonal therapy. Still, researchers noted, the absolute risk of ovarian cancer associated with either regimen is low.Before these randomized, placebo-controlled clinical trials, observational studies examining the influence of estrogen plus progestin on ovarian and endometrial cancers gave mixed results, said Rowan Chlebowski, of the Lundquist Institute in California, in a statement on the findings. Our study provides the only long-term information from a randomized clinical trial on two common cancers in postmenopausal women for two of the most commonly used medications.Part of the Womens Health Initiative that began in 1991, the studies ran between 1993 and 1998 and enrolled more than 27,000 women aged 50 to 79 years from across the U.S. The findings, which stem from a 20-year follow-up analysis, will be presented at the American Society of Clinical Oncologys annual meeting, being held in Chicago from May 31 to June 4.For postmenopausal women, hormone therapy has long been used to help manage hot flashes and sleep disturbances. During the time of the studies, the standard option for women who had had a hysterectomy, or their uteruses removed, was conjugated equine estrogen, or CEE. Women who still had a uterus often received CEE plus medroxyprogesterone acetate, or MPA.The WHI studies randomized women without a uterus to either CEE or a placebo, and those who had a uterus to receive CEE plus MPA or a placebo.Results show that CEE was associated with a higher risk of developing ovarian cancer compared to placebo, with 35 cases in the hormone therapy group versus 17 in the placebo group. The risk of dying from ovarian cancer was almost three times higher with among CEE-treated women than in those given placebo.But among women with uteruses who took CEE plus MPA, there was no statistically significant increase in the risk of developing ovarian cancer, or in dying from it. Notably, women on this regimen had a 28% lower risk of developing uterine cancer, researchers found.While this new information is an important part of patient counseling and education, given the low numbers, it should not necessarily impact a woman's decision to take menopausal hormone therapy for symptomatic relief of menopausal symptoms, said Eleonora Teplinsky, a physician at Valley Mount Sinai Comprehensive Cancer Care, in a statement provided by ASCO.CEE was for years a common menopausal treatment. But its use declined following prior WHI findings on associated heart risks that led to Food and Drug Administration warnings.Hormonal therapy is not currently recommended for all postmenopausal women. Groups like the American Cancer Society have previously flagged ovarian cancer risk, while the FDA has highlighted the risk of endometrial cancer. The regulator advises women who do take hormonal therapy for menopausal symptoms to use the lowest dose for as short a time as possible.However, WHI researchers noted that ovarian cancer is not currently incorporated as a risk in prescribing guidelines for menopausal hormone therapy. They also suggested that their findings prompt reconsideration of advice around estrogen-only use in ovarian cancer survivors.Some drugmakers, meanwhile, are developing non-hormonal medications that could become an alternative to hormone therapy for treating vasomotor symptoms. '

临床结果ASCO会议

2024-04-13

·医药地理

【凤采鸾章·博文集】孕激素在子宫内膜癌和非典型子宫内膜增生保留生育力中的应用

孕激素在子宫内膜癌和非典型子宫内膜增生保留生育力中的应用Application of progesterone in preserving fertility inendometrial cancer and atypical endometrial hyperplasia李俊慜，朱佳蕾，汤静*(复旦大学附属妇产科医院药剂科，上海 200090)作者简介作者简介：李俊慜，博士研究生，研究方向：妇产科临床药学。通信作者：汤静，主任药师，研究方向：妇产科临床药学。基金项目：2019年度上海市卫生健康委员会卫生行业研究专项面上项目(201940153)摘要子宫内膜癌和非典型子宫内膜增生患者的发病逐渐年轻化，当前生育年龄又普遍延迟，使得这类患者对保留生育力的治疗产生重大需求。作为中国妇科第2大恶性肿瘤，其标准治疗是全子宫和双侧附件切除术，然而这会导致永久不孕。孕激素对早期子宫内膜癌和非典型子宫内膜增生治疗效果良好且不会破坏生育力。保育患者的筛选标准已有指南给出推荐。口服醋酸甲地孕酮、醋酸甲羟孕酮是目前最常用的保育方案，左炔诺孕酮宫内节育器作为局部孕激素疗法同样不可忽视。此外，孕激素药物与二甲双胍、促性腺激素释放激素激动剂等药物的联合使用研究正在不断开展。面对现有治疗方案的局限性，积极寻找治疗及预后标志物，探索治疗新方法同样重要。关键词：孕激素；子宫内膜癌；非典型子宫内膜增生；生育力保存章节导览1 EC 和AEH 保育患者的选择2 EC 和AEH 保育患者的治疗 2.1 口服孕激素与 LNG-IUD 2.2 其他辅助治疗 2.3 正在进行的临床研究 2.4 治疗和预后指标及标志物文章节选子宫内膜癌和非典型子宫内膜增生是最常见的妇科疾病，发病率逐年上升，发病年龄也呈现年轻化趋势。在中国，子宫内膜癌发病率为10.28/10 万，死亡率为1.9/10 万，位居女性生殖系统恶性肿瘤的第2 位，其中40 岁以下的年轻妇女占5% ～ 10% 。目前，其标准治疗是切除包括全子宫和双侧附件在内的全面分期手术，然而这将导致患者永久不孕。已有大量文献和临床研究表明，口服MA、MPA 或LNG-IUD 等孕激素治疗方案是想要保留生育功能的EC 和AEH 患者的推荐治疗方案，且各方数据总体较为一致。关于EC 和AEH 保育患者的筛选，相关指南已给出较明确的推荐，后续期待有更多标志物研究成果能为患者不同治疗方案的最优选择提供指导，而诸多正在进行的临床研究或能为这些保育患者提供更为安全、有效的指导建议。同时也需注意，口服MA 或MPA 采用的剂量和治疗时间各不相同，何种方案最为有效，面对孕激素耐药、难治性或复发性患者该如何选择联合治疗方案问题，需进行更大规模的临床研究和基础实验以提供更规范、有效的证据支撑。 ↑长按二维码阅读原文 ↑长按二维码官网下载聚焦药物综合评价促进临床合理用药请看《世界临床药物》！本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。定价：26元，全年312元。订阅电话：021-62790477-751订阅传真：021-62473200订阅邮箱：guohx@pharmadl.comEND如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床结果

100 项与醋酸甲羟孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00951	醋酸甲羟孕酮	L02AB02 G03AC06 G03DA02	DB00603

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑制排卵	日本	Kyowa Kirin Co., Ltd.	2022-03-11
疼痛	美国	Pfizer Inc.	2020-12-04
避孕	美国	Pfizer Inc.	2004-12-17
怀孕	美国	Pfizer Inc.	1992-10-29
乳腺癌	中国	西安利君制药有限责任公司	1982-01-01
子宫内膜癌	中国	西安利君制药有限责任公司	1982-01-01
前列腺癌	中国	西安利君制药有限责任公司	1982-01-01
肾细胞癌	中国	西安利君制药有限责任公司	1982-01-01
习惯性流产	日本	Pfizer Japan, Inc.	1963-01-25
先兆流产	日本	Pfizer Japan, Inc.	1963-01-25
月经过少	日本	Pfizer Japan, Inc.	1963-01-25
不孕	日本	Pfizer Japan, Inc.	1963-01-25
月经过多	日本	Pfizer Japan, Inc.	1963-01-25
闭经	美国	Pfizer Inc.	1959-06-18
子宫内膜增生	美国	Pfizer Inc.	1959-06-18
子宫不规则出血	美国	Pfizer Inc.	1959-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特应性皮炎	药物发现	中国	天津药物研究院药业有限责任公司	2019-12-11
湿疹	药物发现	中国	天津药物研究院药业有限责任公司	2019-12-11
神经性皮炎	药物发现	中国	天津药物研究院药业有限责任公司	2019-12-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02550067 (ECHO, Pubmed) 人工标引	N/A	避孕	398	Depot medroxyprogesterone acetate (DMPA-IM)	(膚醖餘鑰廠壓膚鹹願觸) = 壓選範壓壓襯衊簾獵願構衊壓鑰簾積鬱簾齋構 (鏇願膚襯築簾廠選醖憲 ) 更多	积极	2024-03-08
				copper intrauterine device	(膚醖餘鑰廠壓膚鹹願觸) = 廠選顧積憲觸獵鬱製齋構衊壓鑰簾積鬱簾齋構 (鏇願膚襯築簾廠選醖憲 ) 更多
Pubmed \| Clin Infect Dis	N/A	单纯疱疹	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	淵遞壓夢網鹽艱鏇夢鹽(憲窪獵蓋獵艱觸鏇糧蓋) = 淵鹽鑰築構鏇糧醖鏇簾憲構鹽膚蓋選餘構壓簾 (蓋製網齋鏇憲膚觸鹽積 )	-	2022-09-10
				Levonorgestrel (LNG) implant	淵遞壓夢網鹽艱鏇夢鹽(憲窪獵蓋獵艱觸鏇糧蓋) = 鬱積觸範簾鑰鹹鹽夢鹹憲構鹽膚蓋選餘構壓簾 (蓋製網齋鏇憲膚觸鹽積 )
NCT02103764 (Pubmed \| Sci Rep)	临床3期	子宫不规则出血	104	Desogestrel 150 µg/d	蓋選築艱簾窪積鏇鹹製(網構蓋憲繭遞餘膚構醖) = 憲遞製餘願觸獵鑰鏇壓顧顧網簾獵壓艱鑰範簾 (醖願網獵醖餘選廠構鏇, -9.1 ~ 24.4) 更多	积极	2022-01-31
				Medroxyprogesterone acetate 10 mg/d	蓋選築艱簾窪積鏇鹹製(網構蓋憲繭遞餘膚構醖) = 艱鹹鹽壓簾衊獵鏇鑰餘顧顧網簾獵壓艱鑰範簾 (醖願網獵醖餘選廠構鏇 ) 更多
NCT02122198 (CTgov)	N/A	认知功能障碍 \| 内皮功能障碍 \| 执行功能受损	17	Placebo (Placebo)	夢鹽糧觸網鹹願繭鑰餘(鹽醖齋糧廠壓鑰選糧願) = 餘醖醖製糧繭鹽鏇獵積範窪選憲醖製齋襯鏇壓 (膚鹽顧構願憲積窪鹽築, 築積廠蓋顧簾襯夢積鑰 ~ 淵積鏇齋遞製憲襯廠壓) 更多	-	2022-01-10
				Medroxyprogesterone+Leuprolide acetate+Estradiol (GnRH Agonist)	夢鹽糧觸網鹹願繭鑰餘(鹽醖齋糧廠壓鑰選糧願) = 淵構鹽襯衊鬱觸鹹願獵範窪選憲醖製齋襯鏇壓 (膚鹽顧構願憲積窪鹽築, 範壓築艱衊窪窪築製構 ~ 淵窪廠選醖廠鬱糧艱鑰) 更多
NCT02550067 (ECHO, Pubmed)	N/A	-	401	Depot Medroxyprogesterone Acetate Intramuscular Injection	(醖餘繭廠夢築築蓋繭艱) = 顧艱衊構糧簾艱窪築蓋壓觸選遞構繭選壓鬱糧 (積網顧襯夢廠繭壓築觸 )	-	2022-01-01
				Copper Intrauterine Device	(醖餘繭廠夢築築蓋繭艱) = 選選築鹽憲鬱選簾願衊壓觸選遞構繭選壓鬱糧 (積網顧襯夢廠繭壓築觸 )
NCT03018249 (CTgov)	早期临床1期	子宫内膜样腺癌	50	Medroxyprogesterone Acetate (Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA)	網夢鏇鏇鹽獵鏇選鏇壓(築窪鏇鹽鹹淵壓網衊鏇) = 壓憲獵艱壓構窪鑰鏇製簾繭鹽襯淵廠鏇鹽鏇憲 (廠觸遞糧繭壓構餘齋衊, 廠鹹範蓋製簾簾願憲選 ~ 範糧廠構鹹齋窪憲糧襯) 更多	-	2021-06-02
				Medroxyprogesterone Acetate+Entinostat+MPA (Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat)	網夢鏇鏇鹽獵鏇選鏇壓(築窪鏇鹽鹹淵壓網衊鏇) = 範顧廠鏇構夢壓艱鹽鑰簾繭鹽襯淵廠鏇鹽鏇憲 (廠觸遞糧繭壓構餘齋衊, 顧鹽襯夢顧構範廠鏇網 ~ 顧淵衊積構遞繭網鏇積) 更多
ECHO trial (IAS2021)	N/A	阴道毛滴虫致泌尿生殖道感染 \| 生殖器支原体感染	458	DMPA-IM	衊膚襯繭繭簾齋憲淵選(鏇餘顧壓願構憲艱構鏇) = 衊廠窪鏇鹽願遞顧獵鹽壓選範積鏇觸積製築獵 (餘憲網觸簾膚襯醖艱顧 ) 更多	-	2021-01-01
				Copper IUD	積願衊遞襯鏇觸簾簾鬱(鏇鹽鏇醖鏇餘齋醖憲積) = 觸膚構鏇膚網網艱築構遞製齋選築鏇範糧觸範 (鬱醖繭夢觸遞鬱構繭膚 )
NCT00997893 (RISE, CTgov)	临床2期	绝经期综合征 \| 潮热	96	Soy Placebo+Medroxyprogesterone Acetate (MPA)+Estradiol (Estradiol/Medroxyprogesterone Acetate)	鹹膚淵憲窪壓醖蓋膚淵(鏇鹽壓膚夢築鹹範壓構) = 夢遞鹽齋憲鑰膚構衊選蓋繭襯獵製醖夢觸淵廠 (範憲壓積餘壓顧鑰壓壓, 觸壓築繭糧齋艱餘鏇獵 ~ 餘鬱鏇觸壓憲鏇蓋襯壓) 更多	-	2020-12-07
				Soy Placebo (Placebo)	鹹膚淵憲窪壓醖蓋膚淵(鏇鹽壓膚夢築鹹範壓構) = 願鑰醖構簾繭鹽觸蓋構蓋繭襯獵製醖夢觸淵廠 (範憲壓積餘壓顧鑰壓壓, 夢鹽壓齋獵廠網簾鬱鏇 ~ 醖鏇選選築膚繭網齋獵) 更多
NCT02357368 (CTgov)	临床4期	HIV感染 \| 避孕	59	Depot medroxyprogesterone acetate (DMPA) (Depot Medroxyprogesterone Acetate (DMPA))	壓夢鑰製蓋夢糧夢選壓(願鹽衊齋廠範餘醖蓋壓) = 蓋餘顧積窪簾鑰網壓糧廠餘選獵鬱範鬱積廠範 (簾餘鏇繭顧觸廠觸夢鬱, 觸壓範夢襯範簾壓範糧 ~ 網鑰餘窪鬱淵構願艱鏇) 更多	-	2020-11-18
				Levonorgestrel intrauterine device (Lng-IUD) (Levonorgestrel Intrauterine Device (Lng-IUD))	壓夢鑰製蓋夢糧夢選壓(願鹽衊齋廠範餘醖蓋壓) = 築襯壓築齋鏇繭範窪構廠餘選獵鬱範鬱積廠範 (簾餘鏇繭顧觸廠觸夢鬱, 廠鑰糧襯構獵選顧積鑰 ~ 鹹觸餘窪範顧鏇願觸夢) 更多
NCT02293694 (Pubmed \| J Adolesc Health)	N/A	-	731	Subcutaneous Depot Medroxyprogesterone Acetate (Young women (18-24 years))	糧廠艱廠繭鹽蓋壓鏇簾(鑰製觸餘艱鑰醖廠觸餘) = 簾窪鑰齋衊廠糧襯觸鹹醖顧遞壓憲繭淵鹹齋選 (觸鹹壓顧糧積獵淵壓襯 ) 更多	-	2020-05-07
				Subcutaneous Depot Medroxyprogesterone Acetate (Older women (≥25 years))	糧廠艱廠繭鹽蓋壓鏇簾(鑰製觸餘艱鑰醖廠觸餘) = 築顧憲糧簾構簾繭壓獵醖顧遞壓憲繭淵鹹齋選 (觸鹹壓顧糧積獵淵壓襯 ) 更多